What is the products liability exposure for compounded GLP-1 drugs?

Products liability is the load-bearing line for a compounded GLP-1 operation because the most serious claims typically arise from the compounded product itself - an adverse reaction, a formulation or potency problem, contamination, or a labeling issue. Products and completed operations liability responds to bodily injury caused by the finished compounded drug, and for a compounder that is the central exposure.

The exposure is shaped by several factors: sterile-injectable products carry higher risk than non-sterile, the sourcing and quality of the active ingredient matter, USP 797/800 compliance affects both the risk and the underwriting, and the scale of distribution drives the aggregate. Because GLP-1 drugs are high-demand and high-profile, the litigation and adverse-event environment adds severity.

Products liability works alongside professional liability, which responds to claims arising from the pharmacy's professional judgment. The two are typically placed together, and for a GLP-1 operation the products tower is sized to the sterile-injectable severity and the distribution scale, then confirmed against any contract requirements.